St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).
Derm In The News: September 24-30
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Discovering Dermatology Times: September 2023 BCC Management Supplement
Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata
2 Clarke Drive Cranbury, NJ 08512